Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Analgesics: Considerations for Palliative Care Practice

REFERENCES

• Day JC. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050. US Bureau of the Census, Current Population Reports. Washington, DC: US Government Printing Office; 1996. Publication No. P25-1130.
   Google Scholar
• World Health Organization. Cancer: WHO's pain ladder. Available at: http://www.who.int/cancer/palliative/painladder/en/. Accessed December 7, 2011.
   Google Scholar
• Governale L. Outpatient presciption opioid utilization in the US, years 2000–2009. US Food and Drug Administration Drug Safety and Risk Management Advisory Committee Meeting. July 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ DrugSafetyandRiskManagementADvisoryCommittee/ UCM220950.pdf. Accessed November 16, 2011.
   Google Scholar
• Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain. 2006;7:225–235.
   PubMed Web of Science ®Google Scholar
• Parsells Kelly J, Cook S, Kaufman D, Anderson T, Rosenberg L, Mitchell A. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138:507–513.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July 2010. Available at: http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf. Accessed November 16, 2011.
   Google Scholar
• US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results From the 2009 National Survey on Drug Use and Health: Volume 1. Summary of National Findings. Rockville, MD: Office of Applied Studies; 2010. NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings. Available at: http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf. Accessed November 16, 2011.
   Google Scholar
• Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother. 2010;24:141–144.
   PubMedGoogle Scholar
• US Department of Health and Human Services, US Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/federalfooddrugandcosmeticactfdcact/significantamendments tothefdcact/foodanddrugadministrationamendmentsactof2007/ default.htm. Updated October 21, 2009. Accessed November 16, 2011.
   Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration. Post-approval REMS notification letter. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM251595.pdf. Accessed November 16, 2011.
   Google Scholar
• Chou R, Fanciullo GJ, Fine PG, Opioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;2:113–130.
   Google Scholar
• US General Accounting Office. Prescription drugs, OxyContin Abuse and Diversion, and Efforts to Address the Problem. Washington, DC: US General Accounting Office; 2003. Publication No. GAO-04-110. Available at: http://www.gao.gov/new.items/d04110.pdf. Accessed July 29, 2011.
   Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration. Questions and answers: FDA requires a risk evaluation and mitigation strategy (REMS) for long-acting and extended-release opioids. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm251752.htm. Updated April 14, 2011. Accessed July 29, 2011.
   Google Scholar
• Martins SS, Storr CL, Zhu H, Chilcoat HD. Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population. Drug Alcohol Depend. 2009;99:58–67.
   PubMed Web of Science ®Google Scholar
• Childers JW, Arnold RM. “I feel uncomfortable ‘calling a patient out:’” educational needs of palliative medicine fellows in managing opioid misuse. J Pain Symptom Manage. 2012;43(2):253–260.
   PubMed Web of Science ®Google Scholar
• Rabow MW, Dibble SL, Pantilat SZ, McPhee SJ. The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med. 2004;164: 83–94.
   PubMed Web of Science ®Google Scholar
• Temel JS, Greer JA, Muzikansky A, Early palliative care for patients with metastatic nonsmall-cell lung cancer. N Engl J Med. 2010;363:733–742.
   PubMed Web of Science ®Google Scholar
• Ciemins EL, Blum L, Nunley M, Lasher A, Newman JM. The economic and clinical impact of an inpatient palliative care consultation service: a multifaceted approach. J Palliat Med. 2007;10:1347–1355.
   PubMed Web of Science ®Google Scholar
• Penrod JD, Deb P, Dellenbaugh C, Hospital based palliative care consultation: effects on hospital cost. J Palliat Med. 2010;13:973–979.
   Google Scholar
• Morrison RS, Penrod JD, Cassel JB, et al; Palliative Care Leadership Centers’ Outcomes Group. Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med. 2008;168:1783–1790.
   PubMed Web of Science ®Google Scholar
• Núñez-Olarte JM, Alvarez-Jiménez P. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain. J Pain Symptom Manage. 2011;42:e6–e8.
   Google Scholar
• Patterson TL, Jeste DV. The potential impact of the baby-boom generation on substance abuse among elderly persons. Psychiatr Serv. 1999;50:1184–1188.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The TEDS Report: Changing Substance Abuse Patterns Among Older Admissions: 1992 and 2008. Rockville, MD: Office of Applied Studies; 2010. Publication No. TEDS_229. Available at: wwwdasis.samhsa. gov/teds08/teds2k8natweb.pdf. Accessed January 12, 2012.
   Google Scholar
• Andersen L, Remington P, Trentham-Dietz A, Reeves M. Assessing a decade of progress in cancer control. Oncologist. 2002;7:200–204.
   PubMed Web of Science ®Google Scholar
• Bohnert AS, Valenstein M, Bair MJ, Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315–1321.
   PubMed Web of Science ®Google Scholar
• Dunn KM, Saunders KW, Rutter CM, Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85–92.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network (Dawn Excel Files). National estimates, drug-related emergency department visits, 2004–2009—all visits [patient demographics tabs: 55 to 64 and 65 and older]. Available at: http://www.samhsa.gov/data/DAWN.aspx. Accessed January 10, 2012.
   Google Scholar
• Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27: 417–433.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration. Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications. Rockville, MD: US Department of Health and Human Services; 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM184128.pdf. Accessed January 10, 2012.
   Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Updated December 12, 2011. Accessed January 12, 2012.
   Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research. Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. July 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM217510.pdf. Acces- sed January 10, 2012.
   Google Scholar
• Exalgo (hydromorphone HCl) Extended-Release Tablets CII [medication guide]. Hazelwood, MO: Mallinckrodt Inc.; 2010.
   Google Scholar
• Butrans CIII (buprenorphine) [medication guide]. Stamford, CT: Purdue Pharma L.P.; 2010.
   Google Scholar
• OxyContin (oxycodone hydrochloride controlled-release) Tablets [medication guide]. Stamford, CT: Purdue Pharma L.P.; 2010.
   Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research. Blueprint for prescriber continuing education program. Released October 25, 2011. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ UCM277916.pdf. Accessed December 6, 2011.
   Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration. FDA opioid REMS meeting with industry (May 16, 2011). Silver Spring, MD. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm258184.htm. Accessed August 24, 2011.
   Google Scholar
• Dusetzina SB, Higashi AS, Dorsey ER, Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012 Jan 18 [Epub ahead of print]. doi:10.1097/MLR.06013e318245a160.
   Google Scholar